Medpage Today on MSN1d
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
US FDA-approved diabetes drug shows promise against heart attacks, strokes: Study
A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce heart attacks and ...
Breakthrough medication significantly cuts risk of heart attacks and strokes: Lancet study
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
News Medical on MSN1d
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Mirage News1d
Breakthrough Drug Cuts Heart Attacks, Strokes Risks
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular ...
EurekAlert!2d
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...
‘First of its kind’ medication can significantly reduce heart attacks and strokes
Valentine’s Day has come and gone, but it’s never too late to focus on your heart health.  A groundbreaking new study ...
Medscape4d
The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment
Tubular glucose reabsorption is performed by the combined action of Na + /D-glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of ...
Diabetes drug fights stroke: Medical researchers say Sotagliflozin can reduce heart attacks too
Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...
pharmaphorum6d
Kerendia works in heart failure, but how might it be used?
No effect on cardiovascular death There was discussion at ESC whether Kerendia should be used in place of the SGLT2 inhibitors ... reflects its mechanism of action and hospitalisation rates ...
News Medical on MSN1d
A step toward precision medicine: New drug targets for heart failure
A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...